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SUMMARY
OBJECTIVE—A population-based study of 135 multidrug-resistant tuberculosis (MDR-TB) 
patients reported to the Centers for Disease Control and Prevention (CDC) during 2005–2007 
found 73% were hospitalized. We analyzed factors associated with hospitalization.
METHODS—We assessed statistically significant multivariable associations with US in-patient 
TB diagnosis, frequency of hospitalization, length of hospital stay, and in-patient direct costs to 
the health care system.
RESULTS—Of 98 hospitalized patients, 83 (85%) were foreign-born. Blacks, diabetics, or 
smokers were more likely, and patients with disseminated disease less likely, to receive their TB 
diagnosis while hospitalized. Patients aged ⩾65 years, those with the acquired immune-deficiency 
syndrome (AIDS), or with private insurance, were hospitalized more frequently. Excluding deaths, 
length of stay was greater for patients aged ⩾65 years, those with extensively drug-resistant TB 
(XDR-TB), those residing in Texas, those with AIDS, those who were unemployed, or those who 
had TB resistant to all first-line medications vs. others. Average hospitalization cost per XDR-TB 
patient (US$285 000) was 3.5 times that per MDR-TB patient (US$81 000), in 2010 dollars. 
Hospitalization episode costs for MDR-TB rank third highest and those for XDR-TB highest 
among the principal diagnoses.
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CONCLUSIONS—Hospitalization was common and remains a critical care component for 
patients who were older, had comorbidities, or required complex management due to XDR-TB. 
MDR-TB in-patient costs are among the highest for any disease.
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In the United States, hospitalization is the most expensive component of management of 
tuberculosis (TB), including multidrug-resistant TB (MDR-TB, defined as TB resistant to at 
least isoniazid [INH] and rifampin [RMP]).1,2 Internationally, hospitalization and 
medication costs are the highest cost categories for MDR-TB care.3-5 The World Health 
Organization recommends out-patient MDR-TB treatment, due to its cost effectiveness.6 In a 
US study of human immunodeficiency virus (HIV) negative MDR-TB patients with 
resistance to a median of three drugs, out-patient treatment was feasible.7 To reduce US 
costs and improve care, there is a need to examine why MDR-TB patients are hospitalized in 
the United States.
We recently published the treatment practices, outcomes, and direct cost of illness for a 
population-based sample of 135 MDR-TB cases, including 5 (4%) with extensively drug-
resistant TB (XDR-TB, defined as MDR-TB plus resistance to a fluoroquinolone and to a 
second-line injectable), 23 (17%) with pre-XDR-TB (MDR-TB and resistance to a 
fluoroquinolone or a second-line injectable), 32 (24%) with total first-line resistance, 58 
(43%) with INH/RMP/rifabutin (RBT) resistance plus other resistance, and 17 (13%) with 
INH/RMP/RBT-only resistance.8 Of the 135 study patients, 98 (73%) were hospitalized 
more often (range 1–6), for on average 83 days (median 27) for non-XDR-TB and 357 days 
(median 282) for XDR-TB.8 Severe worsening of disease was the most common reason for 
hospitalization, accounting for 49/98 (50%) hospitalizations.8 Direct in- and out-patient 
costs averaged US$134 000 per MDR-TB patient and US$430 000 per XDR-TB patient, in 
2010 dollars.8
To describe US MDR-TB in-patient care, we 1) identified patient characteristics associated 
with in-patient MDR-TB care, 2) present in-patient direct costs by patient characteristics, 3) 
identified characteristics associated with in-patient MDR-TB direct costs, and 4) compared 
MDR-TB in-patient costs to those of other diseases.
METHODS
The study was approved by the US Centers for Disease Control and Prevention (CDC) and 
local institutional review boards, which granted a waiver for patient informed consent and 
patient authorization. The methods of selecting the population-based sample from California 
(CA), New York City (NYC), and from Texas (TX) of MDR-TB patients reported to the 
CDC in 2005–2007 are described elsewhere.8 The sample included 130 MDR-TB and 5 
XDR-TB cases, representing 36% of MDR-TB and 56% of XDR-TB US-reported cases 
during 2005–2007.
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Direct in-patient costs to the health care system were calculated as follows. In-patient 
charges for hospitalizations during anti-tuberculosis treatment were collected from Medicare 
claims forms and converted to costs using hospital-specific operating cost-to-charge ratios.9 
If a specific hospital’s cost-to-charge ratio was unavailable (n = 33 hospitalizations), the 
state’s average operating-cost-to-charge ratio was used (CA = 0.32, NY = 0.46, TX = 0.40).9 
All costs were converted to 2010 US dollars10 and were adjusted for cost of living (CA = 
1.13, NY = 1.08, TX = 0.94) to facilitate aggregation.11 We added estimated physician 
costs12 of US$238 for a moderately complex first day and US$131 for subsequent days, 
which we converted to costs by multiplying by the average cost-to-charge ratio for 
pulmonary diseases (0.502),13 and updated to 2010 dollars, for cost estimates of US$124 for 
the first day and US$68 for subsequent days. For 17 patients for whom hospitalization 
charge data were unavailable for ⩾1 hospitalization, we estimated the costs by multiplying 
hospitalization length by the average cost per day (US$1419) for patients for whom we had 
detailed data. Hospitalization episode costs were calculated using billing data and compared 
to those of other diseases listed in the Healthcare Cost and Utilization Project (HCUP) 
National In-patient Sample in 2012.14
We classified patients into three levels of illness severity: 1) those with TB-associated death 
during treatment, 2) those with any comorbidities, pregnancy, disseminated or extensive TB 
disease, and 3) those with none of the above factors.
We described in-patient TB diagnosis, hospitalization frequency, length of stay, and direct 
costs by patient characteristics. We assessed days from initial TB diagnosis to starting two or 
more second-line TB medications. Except when assessing the association of illness severity 
with costs, all cost estimates included those of MDR-TB patients who died. We also 
described in-patient insurance status (public/private) and the proportion of total direct costs 
contributed by hospitalization.
We report statistically significant multivariable associations of socio-demographic, clinical, 
and study site characteristics with outcomes: 1) in-patient TB diagnosis (vs. out-patient) 
based on the date of the first positive specimen, treatment start, or report date (using logistic 
regression); 2) hospitalization frequency (using Poisson regression); 3) hospital length of 
stay (using Cox proportional hazards); and 4) in-patient direct costs (using linear 
regression).
Variables in initial models were selected based on prior knowledge2 or expert opinion, and 
included sex, age group, race/ethnicity, foreign birth, homelessness, unemployment, illicit 
substance use, excess alcohol use, smoking, acquired immune-deficiency syndrome (AIDS), 
diabetes mellitus (DM), pregnancy, TB history, disseminated TB, receipt of TB clinic out-
patient care, incarceration in a correctional institution, and long-term care facility residence. 
The hospitalization frequency, length of stay, and cost models also included drug resistance 
pattern, insurance status, and study site. The length of stay model excluded 13 patients who 
died. The hospitalization direct cost model also included hospital length of stay and whether 
a patient died during treatment to assess the intensity of cost by patient characteristic 
including illness severity and to control for the total number of days hospitalized, which 
represents an obvious determinant of total hospitalization cost.
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Multivariable regression was used with backwards elimination of variables insignificant at P 
< 0.05 using SAS version 9.2/9.3 (Statistical Analysis System, Cary, NC, USA). We used 
backwards elimination to help select the final variables most related to the outcome of 
interest. Small sample sizes precluded systematic testing of interaction terms. Adjusted odds 
ratios (aORs) from logistic regression, rate ratios (aRRs) from Poisson regression, hazard 
ratios (aHRs) from Cox proportional hazards survival analysis, and linear regression 
coefficients (β) and their associated 95% confidence intervals (CIs) are reported.
RESULTS
Of 135 patients, 98 (73%) were hospitalized during MDR-TB treatment. Each patient was 
hospitalized for on average 94 days (Table 1). From a review of notations in available 
medical records, multiple reasons for hospitalization were noted. Severe worsening TB was 
the reason for 50% of the hospitalizations, followed by required initiation or changing of the 
treatment regimen (40%), implementation of respiratory isolation (21%), managing adverse 
events (7%), managing concurrent conditions (3%), and surgery (1%).
We were able to determine hospitalization insurance status for 76 of the 98 patients who 
were hospitalized in the 135-patient sample. Of the 76 in-patients, 74% were covered by 
public sector funding (including 24 Medicaid, 4 Medicare, 2 military, 3 jail/prison, 23 with 
no insurance in publicly financed hospitals), 25% by private sources (18 private insurance, 1 
with no insurance in a private hospital), and 1% (1) had other coverage (i.e., unable to be 
classified as public or private).
Black patients (aOR 4.9), diabetics (aOR 3.4), or smokers (aOR 3.1) were more likely to be 
diagnosed with TB while hospitalized, while patients with disseminated disease (aOR 0.1) 
were less likely to receive a TB diagnosis while hospitalized (Table 2). Patients who 
received their TB diagnosis while hospitalized had a significantly shorter time (median 7 vs. 
12 weeks) to start two or more MDR-TB medications (aHR 2.3). MDR-TB patients with a 
history of homelessness (aHR 3.6), a history of injection or non-injection drug use (aHR 
2.4), or with prior TB (aHR 2.3), also had a shorter time to starting MDR-TB treatment. 
Controlling for the preceding factors, it took longer for patients who were recently 
unemployed (aHR 0.4) or had disseminated TB (aHR 0.5) to start two or more MDR-TB 
medications.
Patients with a greater frequency of hospitalizations during MDR-TB treatment included 
those aged ⩾65 years (aRR 2.5), those with AIDS (aRR 2.0), or those with private insurance 
(aRR 1.7) (Table 3).
Excluding those who died during treatment, the length of stay was longer (i.e., aHR of 
having a short length of stay was less) for patients aged ⩾65 years (aHR 0.1), those with 
XDR-TB (aHR 0.1), those residing in Texas (aHR 0.1), those with AIDS (aHR 0.2), those 
with pre-XDR-TB (aHR 0.3), the unemployed (aHR 0.4), or those with resistance to all first-
line medications (aHR 0.5) (Table 4).
While foreign-born patients accounted for 87% (118/135) of the sample and 85% (83/98) of 
hospitalized patients, hospitalizations in this group represented 77% (US$6.7 million/US
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$8.7 million) of the burden of hospitalization cost in this population-based sample (Table 1). 
Costs per hospitalization episode averaged US$54 833 (median US$18 893) for MDR-TB 
and US$191 374 (median US$248 238) for XDR-TB (Table 5). Because MDR-TB patients 
averaged 1.5 hospitalization episodes during treatment, MDR-TB costs per patient averaged 
US$81 212 (median US$45 401) and XDR-TB costs per patient averaged US$285 486 
(median US$319 370).
In bivariate analysis excluding in-patients who died of TB-related causes during MDR-TB 
treatment (n = 9, median US$58 052), costs were significantly greater (P < 0.05) for patients 
with moderate illness severity than for the remaining MDR-TB patients (n = 27, median US
$85 445 vs. n = 61, median US$30 164). However, the multivariable cost model (goodness 
of fit R2 = 0.69) did not retain illness severity after controlling for number of days 
hospitalized (β=US$688): individual in-patient costs were greater for long-term care 
residents (β=US$108 448) or for patients with public insurance (β=US$35 616), and less for 
Texas residents (β=−US$97 984) than for other in-patients.
Hospitalization was the highest MDR-TB cost category, representing 44% of combined 
MDR/XDR-TB costs or, separately, 43% of MDR-TB and 53% of XDR-TB direct costs 
(Figure). The cost of out-patient medications (average US$76 000 or 36% of MDR-TB and 
US$201 000 or 38% of XDR-TB direct costs) was the next highest cost category.
From the HCUP, the average cost (converted to 2010 dollars) for any TB hospitalization 
episode, including drug-susceptible TB, was approximately US$23 000 and ranked 24th 
among 262 principal diagnosis categories.14 If drug-resistant TB were considered separately, 
using costs from this study, MDR-TB in-patient costs (US$55 000 per episode) would rank 
third, after respiratory distress (US$62 000) and pre-term birth (US$58 000), and XDR-TB 
in-patient costs (US$191 000 per episode) would top the list.
DISCUSSION
This study found a high rate of treatment success in a resource-rich setting with 
hospitalization commonly used for MDR-TB treatment. Whether such high success could be 
achieved in the United States without hospitalization could not be addressed in the study. 
However, in the United States, hospitalization remains a critical component of MDR-TB 
care for approximately three fourths of patients, many of whom require complex 
management. MDR-TB patients who were older, had AIDS, had disease resistant to multiple 
anti-tuberculosis medications, or were long-term care residents, had more frequent, longer, 
or more costly hospitalizations.
MDR-TB and XDR-TB patients can be treated primarily in an out-patient setting. However, 
the percentage of MDR-TB patients hospitalized did not change significantly over time 
compared with a 1996 study (73% vs. 71%).2 In our study, patients were hospitalized for 
longer (due to lower mortality, 9% vs. 46%), and had more drug resistance (median 5 
medications, range 2–16 vs. 4, range 2–8), which cost more (median US$24 000, average 
US$51 000 more per patient). Hospitalization of US MDR-TB patients facilitates the 
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application of injectable medications and frequent treatment monitoring, as well as patient 
adherence during the initial phase of treatment.
Diagnosis of TB during hospitalization resulted in more rapid initiation on MDR-TB 
medications. Initial diagnosis of TB while hospitalized was more likely for Blacks, patients 
with DM, or those who smoked. Blacks utilize hospital emergency rooms disproportionately 
more than other racial/ethnic populations, which might have increased their likelihood of an 
in-patient TB diagnosis.15-17 Diabetics and smokers, populations at increased risk of 
progressing to TB disease once infected or having recurrent TB once treated,18,19 might 
have been hospitalized for symptoms associated with those conditions and recognized as 
having TB. Patients with disseminated TB disease were less likely to be diagnosed with TB 
in the hospital, and also had a significantly longer time to MDR-TB diagnosis. Patients with 
disseminated TB often present with a variety of symptoms that takes time for providers to 
assess, and those with extra-pulmonary disease can be difficult to diagnose if TB is not 
initially suspected.
The cost of in-patient care, largely paid for by the public sector, drives the costs of MDR-
TB, and is among the highest for any disease. Although foreign-born MDR-TB patients 
made up 85% of MDR-TB in-patients, their hospitalizations accounted for 77% of the costs 
because they were hospitalized for fewer days than US-born MDR-TB patients. The per-
patient hospitalization cost for XDR-TB (US$285 000) was 3.5 times that for MDR-TB (US
$81 000) in 2010 dollars. The cost per patient was significantly higher for residents of long-
term care facilities or those covered by the public sector (approximately three fourths of 
MDR-TB in-patients). HCUP data corroborate higher hospitalization costs for TB patients 
hospitalized in government-owned rather than in private non-profit or for-profit-owned 
hospitals.14
The main hospital for TB patients in Texas had significantly longer hospitalizations than the 
other study sites, but at a lower average cost per day. Of 14 hospitalized Texas patients, nine 
were known to have received care at the Texas Center for Infectious Disease (TCID) 
Hospital, which specializes in treating patients—typically diagnosed elsewhere—who are 
difficult to manage in an out-patient setting or who have an anticipated long length of stay. 
TCID costs exclude overhead for diagnostic equipment included by acute general hospitals 
for diagnostic services and management of complex comorbidities (J Elkins, TCID Hospital 
Superintendent, personal communication, October 2014). As a publicly funded state 
hospital, TCID’s per diem rates reflect only its high-volume services and state-determined 
salary and benefits rates. In contrast, patients in CA and NYC received care at a variety of 
hospitals.
There appeared to be two MDR-TB care strategies practiced by providers at our study sites: 
1) brief and costly initial hospitalization, followed by a long period of out-patient care, or 2) 
long, publicly funded hospitalization at a specialty facility. While the focus of this paper is 
on hospitalization, we examined whether the strategies had an impact on total (in-patient and 
out-patient) MDR-TB direct costs, and found that the cost averages (P = 0.9) and medians (P 
= 0.8) did not differ significantly among the three study sites. Additional studies would be 
needed to compare MDR-TB care strategies by type of hospital.
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Study limitations included the unavailability of detailed hospitalization data for 17 patients 
and charges data for 11 hospitalizations. Insurance status was only known for 76 
hospitalized patients. Costs for one patient known to be hospitalized could not be estimated 
because we had neither the hospital length of stay nor the hospital charges. Treatment 
adherence through to completion was uniformly high for all studied patients; we could not 
assess whether in-patient care was required to ensure adherence.
CONCLUSIONS
Hospitalization costs for MDR-TB are among the highest for any disease in the United 
States. Patients with MDR-TB who were older, had AIDS, or had more extensive drug-
resistant TB were hospitalized more frequently, for a longer duration, and at a greater cost 
than other MDR-TB patients. Hospitalization remains a critical care component and 
facilitates treatment for these complex cases. Prevention of hospitalization for MDR-TB will 
depend on factors such as the development of new oral medications for treatment, prevention 
of TB-related AIDS, and primary and secondary prevention of multidrug-resistant TB.
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Composition of MDR-TB direct costs in 2010 dollars. MDR-TB = multidrug-resistant 
tuberculosis; XDR-TB = extensively drug-resistant TB; lab = laboratory; DOT = directly 
observed therapy.
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Table 2
MDR-TB patient characteristics and odds of TB diagnosis during hospitalization compared with diagnosis as 
out-patient
Patient characteristic aOR (95%CI)
Black or African American 4.9 (1.3–19.0)
Diabetic, self-report 3.4 (1.3–9.0)
Smoker 3.1 (1.2–8.0)
Disseminated TB* 0.1 (0.01–0.9)
MDR-TB = multidrug-resistant tuberculosis; aOR = adjusted odds ratio; CI = confidence interval.
*Defined as having ⩾2 non-contiguous sites of disease. The following percentages of patients were diagnosed with TB during hospitalization: 57% 
of Black/African Americans, 46% of diabetics, 45% of smokers, and 8% of patients with disseminated disease.
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Table 3
MDR-TB patient characteristics* and rate of hospitalization frequency per patient vs. other MDR-TB patients
Patient characteristic aRR (95%CI)
Age ⩾65 years 2.5 (1.4–4.0)
AIDS 2.0 (1.3–3.1)
Covered by private insurance 1.7 (1.1–2.5)
MDR-TB = multidrug-resistant tuberculosis; aRR = adjusted rate ratio; CI = confidence interval; AIDS = acquired immune-deficiency syndrome.
*Persons aged ⩾65 years, those with AIDS and persons with private insurance during hospitalization comprised respectively 6%, 14% and 19% of 
hospitalized patients.
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Table 4
Patient characteristics and hazard of short length of stay* vs. other in-patients
Patient characteristic aHR (95%CI)
Age ⩾65 years 0.1 (0.02–0.3)
XDR-TB 0.1 (0.02–0.3)




TB resistant to all first-line medications 0.5 (0.3–0.9)
aHR = adjusted hazard ratio; CI = confidence interval; XDR-TB = extensively drug-resistant tuberculosis.
*HR ratios show factors associated with a short period of hospitalization. Those with XDR-TB had a low hazard of a short stay, i.e., had long 
lengths of stay.
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Table 5







Average Median Average Median Average Median
MDR-/XDR-TB 94 28 60 570 19 149 89 636 49 098
MDR-TB 83 27 54 833 18 893 81 212 45 401
XDR-TB 357 282 191 374 248 238 285 486 319 370
MDR-TB = multidrug-resistant tuberculosis; XDR-TB = extensively drug-resistant TB.
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